Publications
222
Citations
4,252
Est. group size
~31
Recurring co-author estimate
Active years
35
Publishing since 1992
Kai He's publication record centers on clinical trials for lung cancer, including cell-based immunotherapies such as tumor-infiltrating lymphocyte (TIL) therapy and targeted drug treatments for tumors with specific genetic mutations. The bibliographic record also includes papers on unrelated topics (extracellular vesicles, stem cell therapy, international relations, agriculture), which likely reflects name overlap with other researchers rather than a single coherent research program.
Publication output has grown substantially over the last decade, rising from single digits in 2017 to a peak of 46 in 2024, though the data likely combines the output of multiple same-named individuals.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Table S3 from Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non–Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors
2026
- Figure S5 from Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non–Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors
2026
- Figure S1 from Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non–Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors
2026
- Figure S3 from Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non–Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors
2026
- Table S2 from Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non–Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors
2026
- Table S1 from Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non–Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors
2026
- Figure S2 from Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non–Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors
2026
- Figure S4 from Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non–Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors
2026
- Extracellular vesicle-induced lipid dysregulation drives liver premetastatic niche formation in colorectal cancer
Gut · 2025
- The positive externalities of US–China institutional balancing in the Indo-Pacific
International Affairs · 2025
- Human induced pluripotent stem cell-derived extracellular vesicles promote neuroprotection effects in rat optic nerve crush model
Experimental Eye Research · 2025
- Abstract CT244: Trial in progress: Phase 1/2 study of OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced solid tumors
Cancer Research · 2025
- BASECAMP-1: An approach to improve patient screening efficiency and to provide large datasets for precision medicine clinical trials.
Journal of Clinical Oncology · 2025
- Abstract CT209: Adagrasib (ADA) as first-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring <i>KRAS</i>G12Cand <i>STK11</i> mutations: KRYSTAL-1 phase 2 cohort
Cancer Research · 2025
- InTriage: Intelligent Telephone Triage in Pre-Hospital Emergency Care
2025
- Journal of Clinical Oncology×34
- Journal of Thoracic Oncology×26
- Cancer Research×10
- Annals of Oncology×8
- Clinical Lung Cancer×6
- Jing Liang
Medicine · The Ohio State University
- Kevin Ho
Medicine · The Ohio State University
- Yan Han
Medicine · Indiana University
- Asrar Alahmadi
Medicine · The Ohio State University
- Lai Wei
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile